The potential for the misinterpretation of positron-emission tomography (PET) scans in the context of a possible malignancy has been confirmed in a case report showing increased 18F-fluorodeoxyglucose (FDG) uptake after unilateral vocal fold augmentation medialization. We sought to expand these findings by investigating FDG uptake in a larger cohort of patients via a retrospective chart review. We examined the records of 15 adults-8 men and 7 women-who had undergone vocal fold augmentation for unilateral vocal fold paralysis and at least one subsequent PET scan. The differences in PET standard uptake value (SUV) between the injected and noninjected vocal folds were assessed via the Wilcoxon signed-rank test. A Spearman rank correlation coefficient was then used to estimate the relationship between differences in PET uptake and the length of time between the injection and the follow-up PET scan. The mean SUV of the injected vocal folds was 3.70, and the mean in the noninjected folds was 2.97. The difference did not achieve statistical significance (p = 0.34). In addition, the rank correlation coefficient with regard to the association between the difference in PET uptake and the duration between injection and PET was -0.24, suggesting an inverse relationship. However, the correlation coefficient did not differ significantly from zero (p = 0.34). We conclude that PET uptake after vocal fold augmentation medialization is variable and that it can increase substantially. This information should be considered in the context of the diagnostic accuracy of malignancy on PET.
Introduction
Office-based laryngologic procedures are being performed significantly more often than in years past. 1 This increase is attributable to improvements in our ability to monitor voice quality; moreover, these procedures are also safer and less expensive than they once were.
Given the inherent morbidity associated with vocal fold paralysis, injection augmentation has only recently evolved as a routine procedure, even though it was first described in an awake patient more than a century ago. 2 Given the proliferation of novel approaches to injection medialization, as well as the advent of novel materials, little is known about the long-term sequelae of these biomaterials in the vocal fold.
A case report by our group in 2008 described increased 18F-fluorodeoxyglucose (FDG) uptake on positron-emission (PET) scanning after injection of calcium hydroxyapatite into a paralyzed vocal fold. 3 This finding is particularly interesting given that a series published by Lee et al in 2005 confirmed the clinical dogma that increased contralateral FDG uptake is quite common in the context of unilateral vocal fold paralysis, possibly because of increased compensatory muscle activity. 4 The combination of these findings underscores the potential for confusion in interpreting PET scans in the setting of a possible malignancy. It also may confirm that there is increased tissue reactivity after injection of this substance, which was previously thought to be relatively inert.
We hypothesized that vocal fold injection medialization might result in increased FDG uptake, likely because of the inherent foreign-body response. This tissue response and associated PET findings have been well documented after injection of polytetrafluoroethylene (Teflon), which is not surprising given its well-documented tissue reactivity. 5 However, injection of calcium hydroxyapatite has more recently been associated with a significant immune response. 6 Therefore, we sought to examine PET findings after vocal fold augmentation in a series of patients. We posited that vocal fold injection would be accompanied by variability with regard to both the degree of enhancement and the duration of FDG uptake after injection. These data likely will increase our understanding of injectate-tissue interactions and potentially circumvent diagnostic uncertainty regarding PET positivity in the context of a potential malignancy.
In this article, we describe our study of FDG uptake after vocal fold injection medialization.
Patients and methods
We conducted a systematic, retrospective chart review to identify patients with unilateral vocal fold paralysis who had undergone both injection medialization and at least one subsequent PET scan. Our exclusion criteria included the presence of thyroid cancer or any other head and neck cancer to avoid the potentially confounding occurrence of PET uptake from a malignancy. Fifteen adults-8 men and 7 women-met our inclusion criteria. Three of the 15 patients had undergone two scans each, and 1 of those patients had received two different injections after each scan (table) .
In addition to demographic data, we compiled information on the location of the primary cancer, the type of injectate, and the interval between the injection and the PET scan. Standard uptake value (SUV), a measure of metabolic activity, was quantified by a single, blinded radiologist.
Differences in PET uptake (SUV) between the injected and noninjected vocal folds were assessed via the Wilcoxon signed rank test with an exact distribution. All observations were assumed to be independent-that is, the PET scans of patients who had undergone multiple scans at different times after vocal fold injection were considered to be unrelated. A Spearman rank correlation coefficient was then employed to estimate the relationship between differences in PET uptake and the length of time between injection and PET scanning. The institutional review boards of the two participating institutions-Memorial Sloan-Kettering Cancer Center and the Weill Cornell Medical College, both in New York City-approved the study.
Results
The two most common forms of cancer were lung cancer (n = 7) and esophageal cancer (n = 4) (table) .
Thirteen patients were injected with calcium hydroxyapatite, and 3 received methylcellulose; 1 patient received both, each on a separate occasion (table). Two of the 3 patients injected with methylcellulose presented with a higher SUV in the injected vocal fold than in the noninjected fold. In the patient who received both, the SUV was higher on the injected side in both instances.
The mean interval between injection and PET ranged from 0.1 to 8.0 months (mean: 3.61) (table) .
The mean SUV was 3.70 in the injected vocal folds and 2.97 in the noninjected vocal folds (table). The SUV value was higher in the injected vocal fold than in the noninjected vocal fold in 10 of the 18 PET scans, it was the same in 3 scans, and it was lower in 5 (figure 1). The difference in PET uptake between the injected and noninjected vocal folds did not achieve statistical significance (p = 0.34).
Statistical analysis of the association between the amount of PET uptake and the interval between injection and PET revealed a correlation coefficient of -0.24, suggesting an inverse relationship. However, the correlation coefficient did not differ significantly from zero (p = 0.34) ( figure 2 ).
Discussion
FDG-PET uses a glucose analog tagged with a positron-emitting isotope to show enhancement in metabolically active tissue. In unilateral vocal fold paralysis, the functioning vocal fold has been shown to be more avid for FDG since it is the more metabolically active of the two vocal folds. 4 Vocal fold bulking ma-terials, which create some degree of tissue reaction, may reverse this phenomenon by preferentially showing enhancement of the paralyzed vocal fold after augmentation.
Injectable fillers have been used for vocal fold augmentation ever since Bruning's 1911 report of paraffin injection into the larynx. 2 Ideally, fillers should promote only minimal tissue reactivity and produce limited migration, predictable durability, and ease of use. Nonautologous fillers used in the more modern era are believed to be slowly phagocytized and degraded by the body without triggering an exuberant inflammatory response.
As mentioned, our group previously reported an increase in PET intensity in association with calcium hydroxyapatite injection. 3 For the present study, we sought to systematically review a series of cases of vocal fold injections and subsequent PET studies to better understand the nature of PET intensity in association with such injections. In our series, SUVs were higher in patients who were injected more recently, but there was no statistical correlation between the degree of PET reactivity and the duration between injection and PET scanning.
It is interesting that 1 patient in our study who was injected with calcium hydroxyapatite exhibited no enhancement on PET 7 months after injection. Variability in SUV values might be attributable to (1) variability in tissue response among individuals, (2) the amount of injectate, (3) the depth of injectate placement in the vocal fold, (4) differences in tissue reactivity among injection substances, and (5) the amount of talking that patients did after the FDG was administered. If an increase in metabolic activity is correlated with tissue degradation of filler, it is feasible that PET uptake may provide information about the expected absorption time of temporary bulking agents.
Only two injectable materials were used in our series: calcium hydroxyapatite and methylcellulose. Analyses of the reactivity of other fillers such as collagen, fat, and permanent materials such as Silastic or Gore-Tex would also be useful.
In conclusion, vocal fold injectates exhibit highly variable PET enhancement. Our study is relevant for the diagnostic interpretation of PET uptake in the face of malignancy. Since our sample size was relatively small, we cannot rule out the possibility of false-nega- Figure 2 . Scatter plot shows the Spearman rank correlation coefficient to estimate the relationship between the difference in FDG uptake in each vocal fold (demonstrating the strength of uptake due to the injection) and the length of time between injection and PET scanning. The analysis showed a correlation coefficient of -0.24, which was not statistically significant (p = 0.34).
Continued from page 220 associated with descending mediastinitis, all 3 of our patients survived with this treatment algorithm.
In conclusion, infections in the pretracheal space represent a rare, potentially severe subset of DNSI. We report what we believe is the first series of idiopathic infections in this space to be published in the English-language literature. A high index of suspicion along with airway management, rapid administration of antibiotics, and surgical drainage represent appropriate treatment, and this approach led to good outcomes for all 3 of our patients, despite the mediastinal involvement.
The presence of an infection in the pretracheal space should alert clinicians to the potential of an underlying malignancy or congenital abnormality, and a thorough investigation for the source of infection is warranted, particularly in the setting of recurrent infection.
